The price of Mobosetinib/Mobosetinib and how much can be reimbursed by medical insurance?

Mobocertinib/Mobocertinib (Mobocertinib) is a new type of tumor treatment drug, which is used to treat patients with non-small cell lung cancer (NSCLC) who have developed EGFR exon 20 insertion mutations. EGFR exon 20 insertion mutation may be one of the main reasons why some patients with non-small cell lung cancer fail to respond to traditional EGFR inhibitor treatment.

Mobosetinib blocks the proliferation and survival signaling pathways of malignant tumor cells by inhibiting the activity of EGFR mutant protein kinase. Clinical trial results show that moboxetinib has significant efficacy in the treatment of non-small cell lung cancer patients with EGFR exon 20 insertion mutations, and can prolong the patient's survival and improve their quality of life.

However, moboxetinib may also cause some side effects, such as gastrointestinal reactions, skin toxicity, etc. Therefore, doctors need to carefully monitor the patient's physical condition during treatment with mobosetinib and adjust the dose or take other treatment measures as needed.

MobosetinibThe original drug is already on the market in China, but it is not included in the medical insurance. The common specifications40mg*112 capsules are priced at about 40,000 yuan per box. Patients cannot use the national medical insurance for reimbursement and can only purchase the drug at their own expense. The Hong Kong clinical version specifications 40mg*30 capsules per box is priced at more than RMB 7,000 (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. Its pharmaceutical ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory 40mg*120 pills per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.